Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 8, Issue 10, Pages 1515-1527Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.8.10.1515
Keywords
analgesia; chronic pain; opioids; oxymorphone
Categories
Ask authors/readers for more resources
Opana (R) ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with low peak-to-trough fluctuations. Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic proper-ties compared with most other opioids, including a longer half-life, higher affinity for the mu-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system. With a safety and tolerability profile similar to other opioids and documented efficacy in several models of chronic pain (low back, cancer, and osteoarthritis), oxymorphone ER provides a new option for clinicians and patients in the treatment of chronic pain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available